Thomas Jefferson University

46 NONPROFIT, COMMUNITY-BASED ORGANIZATIONS AND MEDICAL PROVIDERS IN THE NORTHEAST U.S. COLLABORATE TO 'SHINE THE LIGHT ON SICKLE CELL' ON JUNE 19

Retrieved on: 
木曜日, 6月 13, 2024
Sickle, Museum, SCD, Hospital, Acute chest syndrome, School, Bangladesh Technical Education Board, HRSA, COVID, Movement, Life expectancy, Light, Conference, Thomas Jefferson University, Sickle cell disease, Genetic disorder, Phi Beta Sigma, Social media, House, Hematology, Boathouse Row, Support, Thalassemia, Society, Chronic pain, Depression, Lung, Franklin Institute, Sickle cell trait, HIV, University, Baltimore Ravens, Patient, American Society of Hematology, Division, Disease, Novo Nordisk, Illuminate, Stroke, Medicine, Research, Pharmaceutical industry

PHILADELPHIA, June 13, 2024 /PRNewswire/ -- A collaborative of 46 nonprofit, community-based organizations and medical providers in the Northeast U.S. is set to Shine the Light on Sickle Cell on June 19, World Sickle Cell Awareness Day. This collaborative initiative–which includes the illumination in red of businesses, hospitals, municipal buildings, museums, schools, and other landmarks–aims to unite individuals and communities in support of sickle cell warriors, raise awareness of Sickle Cell Disease (SCD) and advocate for a universal cure. Fraternal organization Phi Beta Sigma Fraternity, Inc., global healthcare company Novo Nordisk Inc., the Baltimore Ravens, and Building Owners Management Association-Philadelphia will also join the campaign that is supported by the federal Health Resources and Services Administration (HRSA) as part of the Sickle Cell Disease Treatment Demonstration Project.

Key Points: 
  • "Our goal is to make Sickle Cell Disease as common a topic as COVID or HIV and to inspire action towards a future where Sickle Cell Disease is better understood, better treated, and ultimately cured."
  • SCD is a genetic blood disorder that disproportionately affects individuals of African descent yet remains widely misunderstood and underrepresented in public discourse.
  • Shine the Light on Sickle Cell primarily operates in the Northeast region, encompassing New England, the mid-Atlantic, Virginia, West Virginia, the U.S. Virgin Islands, and Puerto Rico.
  • Zemoria Brandon is a longtime sickle cell advocate whose husband passed away from the disease in 1998.

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Retrieved on: 
水曜日, 5月 15, 2024
Patient, Risk, Amgen, Drug, Diabetes, University, Drug development, Metabolic bone disease, Fracture, FACP, Osteoporosis, Denosumab, Thomas Jefferson University, Physician, Internal medicine, Metabolism, Roivant Sciences, American College, Eli Lilly, FACE, Thomas Jefferson University Hospital

JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board.

Key Points: 
  • JERUSALEM, May 15, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today announced the appointment of Rachel B Wagman, MD, FACE, FACP, as Key Clinical Advisor and Member of its Scientific Advisory Board.
  • Dr. Wagman brings more than 20 years of metabolic bone disease and women’s health research and drug development experience to Entera.
  • She has successfully advanced the development of five molecules, including the osteoporosis products teriparatide (Forteo®), denosumab (Prolia®) and romosozumab (Evenity®) through clinical development, registration, and lifecycle management.
  • We are extremely excited to welcome Rachel to Entera,” said Miranda Toledano, CEO of Entera.

BostonGene Announces Publication and Journal Cover Feature in Cancer Cell that Unveils a New Immune System Profiling Platform Stratifying Cancer Patients by Treatment Response

Retrieved on: 
火曜日, 5月 14, 2024
Oncology, Health, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Patient, Doctor of Philosophy, Ecology, Thomas Jefferson University, Machine learning, TME, Conditional sentence, Immune system, Tumor microenvironment, Neoplasm, Disease, Drug development, RNA-Seq, Publication, Ageing, Infection, FACS, Cancer, Classification, Immunotherapy, Vaccine

Additionally, disease progression response is affected by the recruitment of immune cells into the tumor and treatments, like immunotherapy, have profound effects on the immune system as well.

Key Points: 
  • Additionally, disease progression response is affected by the recruitment of immune cells into the tumor and treatments, like immunotherapy, have profound effects on the immune system as well.
  • In 2021, BostonGene published a pivotal study in Cancer Cell , revealing the correlation between four conserved tumor microenvironment types to patient responses to immunotherapy.
  • The lack of comprehensive diagnostics and standardized analytical models for assessing the status of a patient's immune system has impeded the widespread adoption of immune system profiling for monitoring treatment and predicting efficacy in cancer patients.
  • To address this unmet need, BostonGene developed an immune system profiling platform using machine learning integration of multiparametric flow cytometry and RNAseq data, characterizing the immune systems of cancer patients.

Slone Partners Places Dr. Eugene P. Kennedy as Chief Medical Officer at Carisma Therapeutics

Retrieved on: 
火曜日, 5月 14, 2024
Patient, Johns Hopkins Hospital, Thomas Jefferson University, Executive search, University, Johns Hopkins, Louisiana State University, IND, Therapy, SVP, Medical college, Senior, Cancer, Genetics, Health, Associate, History, Nursing

SOUTH RIDING, Va., May 14, 2024 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences and healthcare organizations, has announced the placement of Dr. Eugene P. Kennedy, M.D, F.A.C.S. as Chief Medical Officer at Carisma Therapeutics Inc. ("Carisma"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.

Key Points: 
  • as Chief Medical Officer at Carisma Therapeutics Inc. ("Carisma"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies.
  • In his role as Chief Medical Officer, he will be responsible for overseeing Carisma's clinical development, regulatory, and medical affairs functions.
  • Before joining Carisma, Dr. Kennedy served as Chief Medical Officer at Galera Therapeutics, where he oversaw the development of the company's radiotherapy in cancer.
  • "On behalf of Carisma, I am delighted to welcome Gene to our team," said Steven Kelly , President and Chief Executive Officer of Carisma.

Rakuten Medical Announces Poster Presentation and Booth Exhibition at ASCO 2024 Annual Meeting

Retrieved on: 
金曜日, 5月 10, 2024
Safety, Poster, Carcinoma, Research, ASCO, Thomas Jefferson University, Society, Physician, Photoimmunotherapy, Convention, Otorhinolaryngology, Annual general meeting, SAN, Pharmaceutical industry

SAN DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced that it will present a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in Chicago, Illinois from May 31 through June 4, 2024.

Key Points: 
  • SAN DIEGO, May 9, 2024 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy based on its proprietary Alluminox™ platform, today announced that it will present a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (ASCO 2024), which will be held in Chicago, Illinois from May 31 through June 4, 2024.
  • Rakuten Medical will also have a booth in the Exhibit Hall.
  • The Company medical team will be pleased to welcome ASCO participants at booth #12118.
  • First Author: Takeshi Shinozaki, Department of Head and Neck Surgery, National Cancer Center Hospital East, Japan
    For more information and update, follow Rakuten Medical on LinkedIn or visit Rakuten Medical's booth at ASCO 2024.

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
水曜日, 5月 8, 2024
Science, FDA, AMD, Investment, DOI, Safety, OIS, Stuart, Florida, Food, Research, Cleveland Clinic, Growth, FACS, KOL, Therapy, Thomas Jefferson University, Eye, Wills Eye Hospital, Marketing, DME, Clinical trial, Associate, Diabetic retinopathy, ARVO, Plasma, Uveitis, Pharmaceutical industry

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate developments.

Key Points: 
  • The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data in the third quarter of 2024.
  • EyePoint plans to host an R&D Day on June 26, 2024 in New York City.
  • Net product revenue for the first quarter was $0.7 million, compared to net product revenues for the first quarter ended March 31, 2023 of $7.4 million.
  • Operating expenses for the first quarter ended March 31, 2024 totaled $45.0 million versus $29.2 million in the prior year period.

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Retrieved on: 
月曜日, 5月 6, 2024
Duke University Hospital, University, T1D, MACP, SAB, NIH, University of Miami, Psychology, Immunotherapy, Thomas Jefferson University, Research, Immunomodulation, NIDDK, Metabolism, Pediatrics, Pennsylvania State University, FRCP, Internal medicine, Division, Pharmaceutical industry

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.

Key Points: 
  • MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.
  • “Dr.
  • Skyler’s appointment to our Board of Directors is a major milestone for SAB,” said Samuel J. Reich, SAB’s chairman and Chief Executive Officer.
  • “His deep expertise in type 1 diabetes research and leadership in the field will provide insights that will be invaluable to our SAB-142 program.

Merck Manuals: The Facts on Fatty Liver and its New Name

Retrieved on: 
水曜日, 5月 8, 2024
Liver disease, Fatty liver disease, NAFLD, Blood, Blood pressure, MD, Human, Tholey, Thomas Jefferson University, Obesity, Light, Patient, Editorial, Cholesterol, AASLD, Metabolic syndrome, Insulin resistance, Dietary supplement

She also explains why doctors are moving away from the term fatty liver towards more detailed terminology.

Key Points: 
  • She also explains why doctors are moving away from the term fatty liver towards more detailed terminology.
  • In 2023, the American Association for the Study of Liver Disease (AASLD) updated the nomenclature around steatotic liver disease and fatty liver.
  • Fatty liver due to any condition except consumption of large amounts of alcohol was previously called nonalcoholic fatty liver disease (NAFLD).
  • Tholey stresses even social drinking can have a negative effect, and it's not just hard alcohol that can lead to fatty liver.

Susan C. Aldridge, Ph.D., Appointed President of Thomas Jefferson University

Retrieved on: 
火曜日, 5月 7, 2024
Online, Drexel University, Fellow, Textile, Social, Jefferson Health, HHS, Match, Dean, Comprehensive, University of Texas System, Population health, Doctor of Philosophy, Trustee, National Cancer Institute, Research, Colorado Women's College, Success, Thomas Jefferson University, Female, Employment, Engineering, Principal, Nursing, Master's degree, Medicine, Faculty, Century, Troy University, Student, Architecture, Human, Strategic planning, Management

PHILADELPHIA, May 7, 2024 /PRNewswire/ -- Susan C. Aldridge, Ph.D., an accomplished and widely recognized higher education leader, author and strategist who has held executive leadership positions in some of the country's largest universities, has been appointed the first female president of Thomas Jefferson University effective May 7, 2024.

Key Points: 
  • "This is a pivotal moment in Jefferson's history and Dr. Aldridge is the best person to usher in a new era for Thomas Jefferson University," said Jefferson's CEO Joseph G. Cacchione, MD.
  • Her extensive higher education administration experience and visionary leadership make her a natural fit to be our University's next president."
  • "Today, we are a national doctoral research university, and we are part of an anchor organization that also includes Jefferson Health and Jefferson Health Plans.
  • Previously, she was president of the University of Maryland Global Campus and vice chancellor at Troy University.

Jefferson Health Establishes the Stephen and Sandra Sheller Consult and Bridge Program to Provide Person-Centered Care for People with Substance Use Disorder

Retrieved on: 
木曜日, 5月 2, 2024
Family, Public health, Patient, Food, Jefferson Health, Ecosystem, Opioid use disorder, Risk, Housing, Health, The Pew Charitable Trusts, Substance use disorder, FAAFP, Buprenorphine, Methadone, Thomas Jefferson University, Master of Science, Physician, Bridge program, Sheller, Pew, FACP, MPP, Nursing

PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Today, Jefferson Health announced the opening of the Stephen and Sandra Sheller Consult and Bridge Program. The Bridge Program is an ecosystem of coordinated, high-quality care for people with severe substance use disorder. In this model, a single interdisciplinary care team provides comprehensive services for the Bridge patients across community, hospital, emergency department, and psychiatry settings. In addition to the full spectrum of health needs, the program's staff assists patients with social needs such as housing, legal assistance, and food insecurity. The Stephen and Sandra Sheller Consult Bridge Program serves as a vital safe harbor for patients in the earliest stages of medical and substance use recovery.

Key Points: 
  • The Bridge Program is an ecosystem of coordinated, high-quality care for people with severe substance use disorder.
  • The Stephen and Sandra Sheller Consult Bridge Program serves as a vital safe harbor for patients in the earliest stages of medical and substance use recovery.
  • The Bridge Program is an ecosystem of coordinated, high-quality care for people with severe substance use disorder
    "Jefferson Health is committed to creating innovative new programs for delivering compassionate, person-centered care.
  • "We enthusiastically chose Jefferson Health to be the recipient of our foundation funds for this new Stephen and Sandra Sheller Consult and Bridge Program.